Precigen, Inc. (NASDAQ:PGEN) Shares Purchased by CIBC Private Wealth Group LLC

CIBC Private Wealth Group LLC lifted its holdings in Precigen, Inc. (NASDAQ:PGEN) by 29.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 331,476 shares of the biotechnology company’s stock after acquiring an additional 74,422 shares during the period. CIBC Private Wealth Group LLC’s holdings in Precigen were worth $391,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in PGEN. Stifel Financial Corp boosted its position in Precigen by 94.9% during the 3rd quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 15,680 shares during the period. SG Americas Securities LLC boosted its position in shares of Precigen by 27.9% in the fourth quarter. SG Americas Securities LLC now owns 57,641 shares of the biotechnology company’s stock worth $65,000 after buying an additional 12,578 shares during the period. Stoneridge Investment Partners LLC grew its stake in shares of Precigen by 21.3% in the fourth quarter. Stoneridge Investment Partners LLC now owns 68,681 shares of the biotechnology company’s stock valued at $77,000 after buying an additional 12,063 shares in the last quarter. Synovus Financial Corp raised its holdings in shares of Precigen by 100.0% during the 3rd quarter. Synovus Financial Corp now owns 98,130 shares of the biotechnology company’s stock valued at $93,000 after buying an additional 49,065 shares during the period. Finally, Barclays PLC lifted its position in Precigen by 190.4% during the 3rd quarter. Barclays PLC now owns 189,353 shares of the biotechnology company’s stock worth $179,000 after acquiring an additional 124,141 shares in the last quarter. Hedge funds and other institutional investors own 33.51% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on PGEN. JMP Securities reiterated a “market outperform” rating and set a $5.00 price objective on shares of Precigen in a research note on Tuesday, January 14th. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price target on shares of Precigen in a research note on Thursday, March 20th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to data from MarketBeat.com, Precigen has a consensus rating of “Moderate Buy” and a consensus target price of $7.00.

Precigen Stock Down 7.5 %

Shares of NASDAQ PGEN opened at $1.24 on Friday. The business has a 50 day moving average price of $1.68 and a two-hundred day moving average price of $1.19. Precigen, Inc. has a fifty-two week low of $0.65 and a fifty-two week high of $2.17. The firm has a market cap of $364.61 million, a PE ratio of -2.25 and a beta of 1.58.

Precigen (NASDAQ:PGEN) last issued its quarterly earnings results on Wednesday, March 19th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.02. The business had revenue of $1.19 million during the quarter, compared to analyst estimates of $1.30 million. Precigen had a negative net margin of 3,521.68% and a negative return on equity of 123.06%. On average, analysts anticipate that Precigen, Inc. will post -0.32 earnings per share for the current year.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.